News
-
-
-
-
-
-
PRESS RELEASE
GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque
Les nouvelles recommandations de l'EASL-EASD-EASO incluent NIS2+® comme outil-clé pour la détection de la MASH à risque. GENFIT annonce son rôle dans l'identification des patients pour les traitements émergents de la MASH -
PRESS RELEASE
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
GENFIT announces inclusion of NIS2+® in new EASL-EASD-EASO Clinical Practice Guidelines for MASLD, as a key tool for detecting at-risk MASH. Guidelines provide update on prevention, screening, diagnosis, follow-up, and treatment for MASLD -
-
-
PRESS RELEASE
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT achieves historic milestone with U.S. FDA accelerated approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis. Elafibranor tablets approved as first-in-class treatment, marking a significant development in rare liver disease treatment landscape
